Chemerin and prediction of Diabetes mellitus type 2.
Clin Endocrinol (Oxf)
; 82(6): 838-43, 2015 Jun.
Article
en En
| MEDLINE
| ID: mdl-25640450
ABSTRACT
OBJECTIVE:
Insulin resistance and subclinical inflammation are characteristics in the development of type 2 diabetes mellitus (T2DM). The adipokine chemerin has been associated with both factors. The aim of this study was to analyse whether chemerin predicts T2DM.DESIGN:
Blood samples of 440 participants of the Metabolic-Syndrome Berlin-Potsdam (MesyBepo) follow-up study without diabetes at baseline were available for chemerin measurement. Mean follow-up of participants was 5·3 years. Glucose metabolism was analysed using oral glucose tolerance test including insulin measurements. Chemerin was measured using a commercially available ELISA.RESULTS:
Thirty-five individuals developed T2DM during follow-up. Chemerin predicted incident T2DM (Chemerin 1. Tertile reference, 2. Tertile OR 2·33 [0·68-7·95]; Chemerin 3. Tertile OR 3·42 [1·01-11·58] after adjustment for age, sex, BMI, follow-up time, HbA1c, HOMA-IR and WHR). In a secondary analysis, chemerin also predicted worsening of fasting glucose and HbA1c (adjusted for age, sex, BMI, time of follow-up, WHR, HDL cholesterol and triglycerides).CONCLUSIONS:
Our data suggest that chemerin is a weak predictor of T2DM.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Resistencia a la Insulina
/
Quimiocinas
/
Péptidos y Proteínas de Señalización Intercelular
/
Diabetes Mellitus Tipo 2
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Europa
Idioma:
En
Revista:
Clin Endocrinol (Oxf)
Año:
2015
Tipo del documento:
Article
País de afiliación:
Alemania